MedPage Today on MSN
Hemolysis a Growing Concern With Newer Sapien TAVR Device
Since it went on the market, the newer device has been the subject of several reports of hemolysis. This would seem ...
Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.
The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...
Medical Device Network on MSN
Edwards’ JenaValve acquisition nixed as FTC injunction approved by court
Edwards Lifesciences has announced that the US District Court for the District of Columbia has approved an injunction motion ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
On August 6, the Federal Trade Commission (FTC) challenged Edwards Lifesciences Corp.'s proposed $945 million acquisition of JenaValve Technology, Inc. The deal would combine the two leading companies ...
The Centers for Medicare & Medicaid Services has cracked open its coverage policy for transcatheter aortic valve replacement ...
SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback